



2018 Webinar #2: Neonatal “Withdrawal” VS. Neurobehavioral Deficits

April 5th, 2017

Presented by Ira J. Chasnoff, MD

REFERENCES

Ailes EC, Dawson AL, Lind JN, et al. Opioid prescription claims among women of reproductive age--United States, 2008-2012. *MMWR Morb Mortal Wkly Rep* 2015; 64:37.

American Academy of Pediatrics: Committee on Drugs. Neonatal drug Withdrawal. *Pediatrics* 1998;129(2):e540.

Bada HS, Das A, Bauer CR, et al. Low birth weight and preterm births: etiologic fraction attributable to prenatal drug exposure. *J Perinatol* 2005; 25:631.

Bauer CR, Langer JC, Shankaran S, et al. Acute neonatal effects of cocaine exposure during pregnancy. *Arch Pediatr Adolesc Med* 2005; 159:824.

Bernard C, Milh M, Morozoy YM Ben-Ari Y, Freund TF, Gozlan H. Altering cannabinoid signaling during development disrupts neuronal activity. *Proc Natl Acad Sci USA*. 2005;102:9388-9393.

Chasnoff IJ, Griffith DR, MacGregor S, Dirkes K, and Burns KA. Temporal Patterns of Cocaine use in Pregnancy: Perinatal Outcome. *J.A.M.A.* Vol 261, No. 12, March 24, 1989, 1741-1744.

Chasnoff IJ, Burns WJ and Hatcher R. Polydrug - and Methadone -Addicted Newborns: a Continuum of Impairment? *Pediatrics* 70:210-212, 1982.

Chasnoff IJ, Burns WJ, Schnoll SH and Burns K. Pentazocine and Pyribenzamine ("T's and Blue's): Effects on the Fetus and Neonate. *Develop Pharm Therap* 6:162-169, 1983.

Chasnoff IJ, Burns WJ, Schnoll SH and Burns K. Phencyclidine: Effects on the Fetus and Neonate. *Develop Pharm Therap* 6:404-408, 1983.

Chasnoff IJ, Burns WJ and Schnoll SH. Perinatal Addiction: Maternal Narcotic vs. Non-narcotic Use During Pregnancy and its Effects on Infant Development. In: *Problems of Drug Dependence* 1983. 49:220-226, N.I.D.A., 1984.

Chasnoff IJ and Burns WJ. The Moro Reaction: A Scoring System for Neonatal Narcotic Withdrawal. *Develop Med Child Neurol* 26:484-489, 1984.

Chasnoff IJ, Schnoll SH, Burns WJ and Burns K. Maternal Substance Abuse During Pregnancy: Effects on Infant Development. *Neurobehav Toxicol Teratol* 6:277-280, 1984.

Chasnoff IJ, Burns WJ, Schnoll SH, and Burns KA. Cocaine Use in Pregnancy. *New England Journal of Medicine* 313:666-669, 1985.



Chasnoff IJ. Effects of Maternal Narcotic vs. Non-narcotic Addiction on Neonatal Neurobehavior and Infant Development. In: Current Research on the Consequences of Maternal Drug Use, T.M. Pinkert (ed.), N.I.D.A. Washington, D.C. 59:84-95, 1985.

Choo RE, Huestis MA, Schroeder JR, et al. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. *Drug Alcohol Depend* 2004; 75:253.

Cleary BJ, Eogan M, O'Connell MP, Fahey T, Gallagher PJ, Clarke T, et al. Methadone and perinatal outcomes: a prospective cohort study. *Addiction*. 2012;107:1482–1492. [[PubMed](#)]

Coyle MG, Salisbury AL, Lester BM, Jones HE, Lin H, Graf-Rohrmeister K, et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. *Addiction*. 2012;107:63–73.

Desmond MM, Schwanecke RP, Wilson GS, et al. Maternal barbiturate utilization and neonatal withdrawal symptomatology. *J Pediatr* 1972; 80:190.

Fried PA, Makin JE. Neonatal behavioral correlates of prenatal exposure to marijuana, cigarettes, and alcohol in a low risk population. *Neurotoxicology and Teratology*. 1987;9:1-7.

Fulroth R, Phillips B, Durand DJ. Perinatal outcome of infants exposed to cocaine and/or heroin in utero. *Am J Dis Child* 1989; 143:905.

Golden NL, Kuhnert BR, Sokol RJ, et al. Neonatal manifestations of maternal phencyclidine exposure. *J Perinat Med* 1987; 15:185.

Hansen RL, Struthers JM, Gospe SM Jr. Visual evoked potentials and visual processing in stimulant drug-exposed infants. *Dev Med Child Neurol* 1993; 35:798.

Hudak ML, Tan RC, COMMITTEE ON DRUGS, et al. Neonatal drug withdrawal. *Pediatrics* 2012; 129:e540.

Huybrechts KF, Bateman BT, Desai RJ, et al. Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study. *BMJ* 2017; 358:j3326.

Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. *Psychiatr Serv* 2002; 53:39.

Janssen LM, Di Pietro JA, Elko A, et al. Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes. *Drug Alcohol Depend* 2012; 122:213.

Jansson LM, Velez M. Neonatal abstinence syndrome. *Curr Opin Pediatr* 2012; 24:252.

Maraes Barros MC, Guinsburg R, Araujo Peres, C. Exposure to marijuana during pregnancy alters neurobehavior in the early neonatal period. *J Pediatrics*. 2006;149:781-787.

Mayes LC, Carroll KM. Neonatal withdrawal syndrome in infants exposed to cocaine and methadone. *Subst Use Misuse* 1996; 31:241.



Patrick SW, Schumacher RE, Benneyworth BD, et al. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 2012; 307:1934.

Patrick SW, Dudley J, Martin PR, et al. Prescription opioid epidemic and infant outcomes. Pediatrics 2015; 135:842.

Pichini S, Garcia-Algar O. In utero exposure to smoking and newborn neurobehavior: how to assess neonatal withdrawal syndrome? Ther Drug Monit 2006; 28:288.

Pierog S, Chandavas O, Wexler I. Withdrawal symptoms in infants with the fetal alcohol syndrome. J Pediatr 1977; 90:630.

Robe LB, Gromisch DS, Iosub S. Symptoms of neonatal ethanol withdrawal. Curr Alcohol 1981; 8:485.

Smith L, Yonekura ML, Wallace T, et al. Effects of prenatal methamphetamine exposure on fetal growth and drug withdrawal symptoms in infants born at term. J Dev Behav Pediatr 2003; 24:17.

Wachsman L, Schuetz S, Chan LS, Wingert WA. What happens to babies exposed to phencyclidine (PCP) in utero? Am J Drug Alcohol Abuse 1989; 15:31.



Notes